PMID- 24809013
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140508
LR  - 20211021
IS  - 2233-8276 (Print)
IS  - 2233-8268 (Electronic)
IS  - 2233-8276 (Linking)
VI  - 4
IP  - 2
DP  - 2014 Apr
TI  - Pholcodine consumption and immunoglobulin E-sensitization in atopics from 
      Australia, Korea, and Japan.
PG  - 86-90
LID - 10.5415/apallergy.2014.4.2.86 [doi]
AB  - BACKGROUND: Accumulating data indicates that pholcodine (PHO)-consuming countries 
      have higher sero-prevalences of immunoglobulin E (IgE)-antibodies to PHO and 
      suxamethonium (SUX) and increased frequencies of IgE-mediated anaphylaxis to 
      neuromuscular blocking agents (NMBAs) than nonconsuming. Withdrawing 
      PHO-containing cough syrups resulted in a significant decrease of cases with 
      anaphylaxis in Scandinavia. Nevertheless, the European Medicines Agency in 2011 
      advised to continue the unrestricted use throughout the European Union. 
      OBJECTIVE: To extend studies on PHO consumption and prevalence of 
      IgE-sensitization to morphine (MOR), PHO, and SUX to countries representing high 
      (Australia), and low (Korea and Japan), consumers, respectively. METHODS: 
      IgE-antibodies to SUX, MOR, and PHO in atopic subjects were determined by 
      immunoassay and compared with official figures for PHO consumption and reported 
      anaphylaxis to NMBA. RESULTS: The prevalences of IgE-antibodies to PHO, MOR, and 
      SUX were 10%, 8.6%, and 4.3%, respectively, in Australia. The corresponding 
      figures for Japan were 0.8%, 0.8%, and 1.5%, and for Korea 1.0% to PHO and 0.5% 
      to MOR and SUX. Of the SUX-positive sera, 100% were positive to PHO or MOR in 
      Australia and 0% in Japan and Korea. CONCLUSION: The study supports previous 
      findings; exposure to PHO may induce IgE-antibodies to the substituted ammonium 
      ion epitope of NMBAs, thus increasing risk of NMBA-induced anaphylaxis 
      considerably. However, other, still unknown factors occasionally might induce 
      IgE-antibodies to SUX.
FAU - Katelaris, Constance H
AU  - Katelaris CH
AD  - Campbelltown Hospital, University of Western Sydney, Sydney 2560, Australia.
FAU - Kurosawa, Motohiro
AU  - Kurosawa M
AD  - Gunma Institute for Allergy and Asthma, Tatebayashi-Kosei Hospital, Tatebayashi 
      374-0055, Japan.
FAU - Moon, Hee-Bom
AU  - Moon HB
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan Collage 
      of Medicine, Seoul 138-736, Korea.
FAU - Borres, Magnus
AU  - Borres M
AD  - Department of Women's and Children's Health, Uppsala University, Thermo Fisher 
      Scientific, Uppsala 751 05, Sweden.
FAU - Florvaag, Erik
AU  - Florvaag E
AD  - Laboratory of Clinical Biochemistry, Department of Occupational Medicine, 
      Haukeland University Hospital, Bergen 0027, Norway. ; Department of Clinical 
      Science, University of Bergen, Bergen N-5020, Norway.
FAU - Johansson, Stig Gunnar Olof
AU  - Johansson SG
AD  - Department of Medicine, Clinical Immunology and Allergy Unit, Karolinska 
      University Hospital, Stockholm SE-141 86, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20140429
PL  - Netherlands
TA  - Asia Pac Allergy
JT  - Asia Pacific allergy
JID - 101561954
PMC - PMC4005347
OTO - NOTNLM
OT  - Anaphylaxis
OT  - General anaesthesia
OT  - IgE
OT  - Neuromuscular blocking agent
OT  - Pholcodine
EDAT- 2014/05/09 06:00
MHDA- 2014/05/09 06:01
PMCR- 2014/04/01
CRDT- 2014/05/09 06:00
PHST- 2014/04/03 00:00 [received]
PHST- 2014/04/11 00:00 [accepted]
PHST- 2014/05/09 06:00 [entrez]
PHST- 2014/05/09 06:00 [pubmed]
PHST- 2014/05/09 06:01 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - 10.5415/apallergy.2014.4.2.86 [doi]
PST - ppublish
SO  - Asia Pac Allergy. 2014 Apr;4(2):86-90. doi: 10.5415/apallergy.2014.4.2.86. Epub 
      2014 Apr 29.